BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27

• 

  Drug pricing

  Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU

  In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing initiatives as he touted his efforts to lower healthcare costs for Americans.

  February 25, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Vaccines

  Postponed ACIP Meeting Rescheduled for Mid-March

  The rescheduling of the Advisory Committee on Immunization Practices comes amid fresh leadership upheaval at the CDC as NIH director Jay Bhattacharya replaces Jim O’Neill as acting head of the agency.

  February 25, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B

  After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is throwing more money into the obesity space, striking a deal with Vivtex to advance novel weight loss pills.

  February 25, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility

  The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.

  February 25, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Regulatory

  Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study

  A trial of a MacroGenics’ drug temporarily paused enrollment after several safety events, including a fatality. The deceased patient had developed a severe case of neutropenia and concurrent septic shock.

  February 25, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Startups

  Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody

  Solstice Oncology will gain an exclusive worldwide license to Harbour BioMed’s porustobrt, an anti-CTLA-4 antibody currently being studied for melanoma, colorectal cancer and other malignancies in China.

  February 25, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home

  When Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed a fierce passion for the therapeutic area. He will step aside from his role to dedicate more time to his family.

  February 25, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Opinion

  Balancing Safety Access in Rare Disease—Lessons From Sarepta

  Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.

  February 25, 2026

   · 

  6 min read

   · 

  Joshua R. Mansbach
• 

  IPO

  How LB Rode the Brutal Capital Markets to One of 2025’s Most Successful IPOs

  LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.

  February 25, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Rare diseases

  Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D

  Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to solve what CEO Craig Martin says is not a science problem, but a math problem.

  February 25, 2026

   · 

  7 min read

   · 

  Heather McKenzie